Engel-Riedel W, et al. - BTH1677, a beta-glucan pathogen-associated molecular pattern molecule, drives an anti-cancer immune response in combination with oncologic antibody therapies. In this phase II trial, it was demonstrated that compared with control treatment, BTH1677/bevacizumab/carboplatin/paclitaxel resulted in improvements in tumor assessments and survival in treating advanced non-small cell lung cancer (NSCLC).